选择性11β-HSD1抑制剂AZD4017对绝经后骨量减少女性骨转换标志物的影响
这项双中心、II期、随机双盲安慰剂对照试验在55例绝经后骨量减少女性中评估AZD4017(选择性11β-HSD1抑制剂)400 mg每日两次口服90天对骨形成标志物骨钙素的影响。90天时骨钙素在活性组与安慰剂组间无差异,基线校正后疗效估计为0.95(95%CI:-2.69,4.60)。AZD4017在体内安全、可逆地选择性抑制11β-HSD1活性,但对骨形成无影响。
要点
- 90天时骨钙素活性组均值22.3(SD 8.6)ng/mL(n=22)vs 安慰剂组21.7(SD 9.2)ng/mL(n=24),无差异。
- 基线校正后疗效估计为0.95(95%CI:-2.69,4.60),未达统计学显著。
- 尿[THF+alloTHF]/THE比值证实11β-HSD1抑制>90%,11β-HSD2活性无变化。
核心结论
- AZD4017在体内安全、可逆地选择性抑制11β-HSD1活性;治疗90天后对骨形成无影响,提示正常生理浓度下绝经后女性骨密度相对受损并非由局部细胞内皮质醇生成介导。
研究设计与样本
- 双中心、II期、随机、双盲、安慰剂对照试验,纳入55例绝经后骨量减少女性,AZD4017 400 mg口服每日两次 vs 匹配安慰剂治疗90天。
主要发现
- 90天时骨钙素水平活性组均值22.3(SD 8.6)ng/mL(n=22)vs 安慰剂组均值21.7(SD 9.2)ng/mL(n=24),基线校正后疗效估计0.95(95%CI:-2.69,4.60)。
- 尿[THF+alloTHF]/THE比值(11β-HSD1活性指标)和尿皮质醇/可的松比值(11β-HSD2活性指标)证实11β-HSD1抑制>90%,11β-HSD2活性无变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The causative link between circulating glucocorticoid excess and osteoporosis is well-established. The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which increases local cortisol production, is expressed in human osteoblasts and its activity increases with age. OBJECTIVE: We hypothesized that local 11β-HSD1 might mediate an age-related decrease in bone formation and that selective 11β-HSD1 inhibition may enhance bone formation. METHODS: A dual-center, phase II, randomized, double-blind, placebo-controlled trial of 90 days' treatment with AZD4017 (a selective 11β-HSD1 inhibitor) was conducted in 55 postmenopausal women with osteopenia. Participants received 400 mg oral AZD4017 twice daily vs matched placebo over 90 days. The primary outcome measure was the impact on the bone formation marker osteocalcin. Secondary objectives included correlation with 11β-HSD1 activity. RESULTS: At 90 days, osteocalcin levels did not differ between treatment groups: active (mean 22.3 [SD 8.6] ng/mL, n = 22) and placebo (21.7 [SD 9.2] ng/mL, n = 24), with a baseline-adjusted treatment effect of 0.95 (95% CI: -2.69, 4.60). The results from the urinary [THF + alloTHF]/THE ratio (index of 11β-HSD1 activity) and the urinary cortisol/cortisone ratio (index of 11β-HSD2 activity) confirmed a > 90% inhibition of 11β-HSD1 but no change in activity of 11β-HSD2. CONCLUSION: This trial demonstrates that AZD4017 selectively inhibits 11β-HSD1 activity in vivo in a safe and reversible manner. Following 90 days of treatment, there is no effect on bone formation, indicating that the relative impairment of bone mineral density in postmenopausal women is not mediated by local intracellular production of cortisol under normal physiological concentrations.
引用
- Abbas A, Schini M, Ainsworth G, et al. Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia. J Clin Endocrinol Metab. 2022. PMID: 35275196. doi:10.1210/clinem/dgac100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。